Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) - Adventist HealthCare

Skip to Content

Clinical Trial Details


Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)


Request Additional Trial Information
Full Trial Details:

Condition: Urothelial Cancer
Study Type: Interventional
Phase: Phase II
Study Start Date: 01/07/2015
Study Completion Date: TBD

This is a study using pembrolizumab for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. The primary study hypothesis is that pembrolizumab treatment will result in a clinical meaningfully overall response rate (ORR) in participants whose tumors rely on programmed cell death ligand 1 (PD-L1) protein.

NCT Number
Principal Investigator(s)
Mohit Narang, MD
Merck Sharp & Dohme Corp
Participant Eligibility
  • Age: 18 - No Maximum
  • Gender: Male


  • Shady Grove Adventist Aquilino Cancer Center
    9905 Medical Center Drive
    Rockville, MD 20850
    Main: 240-826-6297

Clincal Trials & Research Studies

Patient Stories

We’re writing new chapters in the lives of our patients, their families and our community daily. These are their stories:

Local Health News - In Your Inbox

Join over 100k of your friends & neighbors and get the latest news about community health programs and events when you sign-up for Adventist HealthCare & You Digital.

Subscribe Today!